Q-omics provides the consensus-scored KLF5 profile across patient tissues and cancer cell-line models. KLF5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, KLF5 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KLF5 protein abundance shows 32,119 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KIRC, and LSCC as cancer lineages where KLF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF5 survival associations across molecular data types. KLF5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF5 RNA expression–survival associations across cancer types. High KLF5 expression shows unfavorable associations in LUAD, KIRP and PAAD, but favorable associations in LUSC, KIRC and CESC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for KLF5 RNA expression.
This table summarizes KLF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF5 shows lower tumor expression in KIRC, KICH and BRCA and higher tumor expression in LUSC, STAD and CHOL. The KIRC box plot shows higher KLF5 RNA expression in normal versus tumor tissue (log2 FC = −2.062, t-test p < 0.001).
This table shows molecular features associated with KLF5 in patient tissues and cancer cell lines. In patient samples, KLF5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
